HUP0103091A3 - Process for purifying human papillomavirus virus-like particles - Google Patents

Process for purifying human papillomavirus virus-like particles

Info

Publication number
HUP0103091A3
HUP0103091A3 HU0103091A HUP0103091A HUP0103091A3 HU P0103091 A3 HUP0103091 A3 HU P0103091A3 HU 0103091 A HU0103091 A HU 0103091A HU P0103091 A HUP0103091 A HU P0103091A HU P0103091 A3 HUP0103091 A3 HU P0103091A3
Authority
HU
Hungary
Prior art keywords
particles
human papillomavirus
purifying human
papillomavirus virus
virus
Prior art date
Application number
HU0103091A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HUP0103091A2 publication Critical patent/HUP0103091A2/hu
Publication of HUP0103091A3 publication Critical patent/HUP0103091A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0103091A 1998-08-14 1999-08-10 Process for purifying human papillomavirus virus-like particles HUP0103091A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9656898P 1998-08-14 1998-08-14
PCT/US1999/017930 WO2000009671A1 (en) 1998-08-14 1999-08-10 Process for purifying human papillomavirus virus-like particles

Publications (2)

Publication Number Publication Date
HUP0103091A2 HUP0103091A2 (hu) 2001-12-28
HUP0103091A3 true HUP0103091A3 (en) 2002-03-28

Family

ID=22257989

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103091A HUP0103091A3 (en) 1998-08-14 1999-08-10 Process for purifying human papillomavirus virus-like particles

Country Status (24)

Country Link
US (1) US6602697B1 (hu)
EP (1) EP1105466B1 (hu)
JP (1) JP4440471B2 (hu)
KR (1) KR20010072470A (hu)
CN (1) CN1354787A (hu)
AT (1) ATE324436T1 (hu)
AU (1) AU760633B2 (hu)
BR (1) BR9913026A (hu)
CA (1) CA2339034C (hu)
CY (1) CY1105084T1 (hu)
CZ (1) CZ2001570A3 (hu)
DE (1) DE69931053T2 (hu)
DK (1) DK1105466T3 (hu)
EA (1) EA200100236A1 (hu)
ES (1) ES2262333T3 (hu)
HR (1) HRP20010113A2 (hu)
HU (1) HUP0103091A3 (hu)
IL (1) IL141130A0 (hu)
NZ (1) NZ509610A (hu)
PL (1) PL347472A1 (hu)
PT (1) PT1105466E (hu)
SI (1) SI1105466T1 (hu)
SK (1) SK2232001A3 (hu)
WO (1) WO2000009671A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266604A3 (en) * 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
JP2000262280A (ja) * 1999-03-18 2000-09-26 Asahi Optical Co Ltd ウィルスまたはウィルス性抗原の精製方法およびワクチンの製造方法
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
SG150501A1 (en) * 2004-02-05 2009-03-30 Millipore Corp Porous adsorptive or chromatographic media
KR101203403B1 (ko) * 2004-03-24 2012-11-21 머크 샤프 앤드 돔 코포레이션 효모에서 ｈｐｖ 52 ｌ1의 최적화된 발현
DE602005022458D1 (de) 2004-09-10 2010-09-02 Asahi Glass Co Ltd Impfstoff gegen humanes papillomavirus zur oralen verabreichung
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
US20100288029A1 (en) * 2006-08-30 2010-11-18 Ge Healthcar Bio-Sciences Corp. System and method for characterizing membranes and membrane filtration devices
PL2601969T3 (pl) 2006-09-29 2016-10-31 Preparaty szczepionki przeciw norowirusowi
CN101616930B (zh) * 2007-02-22 2013-05-08 巴克斯特国际公司 疏水性蛋白质的纯化方法
ES2559421T3 (es) 2007-03-14 2016-02-12 Takeda Vaccines, Inc. Purificación de partículas similares a virus
WO2008134934A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. A truncated l1 protein of human papillomavirus 16
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
BRPI0810951B8 (pt) * 2007-05-29 2021-05-25 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR20150129042A (ko) * 2007-09-18 2015-11-18 다케다 백신즈 인코포레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
DE602007007927D1 (de) * 2007-11-05 2010-09-02 Agilent Technologies Inc Einfrierung eines mikrofluidischen Chips
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
ES2668836T3 (es) 2008-08-08 2018-05-22 Takeda Vaccines, Inc. Partículas similivíricas que comprenden secuencias de aminoácidos de la cápside compuestas para reactividad cruzada potenciada
CA2787009C (en) 2010-01-15 2018-04-03 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
US9592540B2 (en) 2011-02-02 2017-03-14 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
WO2013080187A1 (en) * 2011-12-01 2013-06-06 University Of Cape Town Hpv chimaeric particle
CN104507952B (zh) 2012-05-30 2018-08-10 生物辐射实验室股份有限公司 基于磷灰石的色谱树脂的原位恢复
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
EP3157689B1 (en) 2014-06-23 2021-04-28 Bio-Rad Laboratories, Inc. Apatite pretreatment
EP3157551B1 (en) 2014-06-23 2023-02-15 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
CN108524929B (zh) * 2017-03-06 2019-05-07 广州瑞贝斯药业有限公司 一种狂犬病疫苗的生产方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6078999A (ja) 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
SE9000650L (sv) * 1989-02-28 1990-08-29 Asahi Optical Co Ltd Separation av celler eller virus
CZ336696A3 (en) * 1994-05-16 1997-07-16 Merck & Co Inc Isolated and purified proteins of papillomavirus and process for preparing thereof
SK35897A3 (en) * 1994-09-22 1998-02-04 Merck & Co Inc Isolated and purified dna molecule, encoding human papillomavirus type 6a, method of expression, pharmaceutical composition, a vaccine and use
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
CA2230655C (en) 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav

Also Published As

Publication number Publication date
PT1105466E (pt) 2006-07-31
JP2003520188A (ja) 2003-07-02
JP4440471B2 (ja) 2010-03-24
CA2339034A1 (en) 2000-02-24
SI1105466T1 (sl) 2006-08-31
CZ2001570A3 (cs) 2001-09-12
AU5469899A (en) 2000-03-06
WO2000009671A1 (en) 2000-02-24
ATE324436T1 (de) 2006-05-15
EP1105466B1 (en) 2006-04-26
CA2339034C (en) 2010-10-12
CN1354787A (zh) 2002-06-19
SK2232001A3 (en) 2001-08-06
DE69931053D1 (de) 2006-06-01
HRP20010113A2 (en) 2002-02-28
US6602697B1 (en) 2003-08-05
AU760633B2 (en) 2003-05-22
PL347472A1 (en) 2002-04-08
EP1105466A4 (en) 2002-05-15
EP1105466A1 (en) 2001-06-13
KR20010072470A (ko) 2001-07-31
ES2262333T3 (es) 2006-11-16
EA200100236A1 (ru) 2001-08-27
IL141130A0 (en) 2002-02-10
DE69931053T2 (de) 2006-11-23
DK1105466T3 (da) 2006-08-14
NZ509610A (en) 2002-10-25
BR9913026A (pt) 2001-09-25
HUP0103091A2 (hu) 2001-12-28
CY1105084T1 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
HUP0103091A3 (en) Process for purifying human papillomavirus virus-like particles
IL143381A0 (en) Method for separating viral particles
HUP0203278A3 (en) Apparatus and process for preparing crystalline particles
PL349345A1 (en) Apparatus and process for preparing crystalline particles
HK1062170A1 (en) Process for the preparation of 1,3-substituted in denes and aryl-fused azapolycyclic compounds
PL352355A1 (en) Filter for particles, made of metal foil
AU4316299A (en) Oral immunization with papillomavirus virus-like particles
IL129906A0 (en) Process for the preparation of beta-isophorone
GB9420146D0 (en) Papillomavirus vaccine
GB9911781D0 (en) Process for preparing phosphor particles
AU2001216482A1 (en) High functional water containing titanium and method and apparatus for producing the same
AU2001263046A1 (en) Process for preparing chitosan particles
AU3588300A (en) Method for removing suspended particles using mannich-derived polyethers
HUP0203407A3 (en) Process for the preparation of pyrazolopyridazine derivatives
GB9607899D0 (en) Virus-like particle
PL345068A1 (en) Novel compounds derived from α-d-xylose, preparation method and therapeutic use
IL138691A (en) Process for the preparation of 3-acyl-indoles
HUP0202865A3 (en) Process for the preparation of 2-cyanopyridines
HUP0103569A2 (hu) Új gyógyszerkészítmény és eljárás az előállítására
HUP9902745A2 (en) Process for the preparation of benzylcarbazate
AU4102000A (en) Method for representing biologically activated inductance-altering particles anddevice for carrying out the method
AU4157800A (en) Method for the preparation of particles
AU2166302A (en) Process for the preparation of thiophenols
HUP0303030A3 (en) Method for purifying 20(s)-camptothecin
AU2002244711A1 (en) Method for purifying 20(S)-camptothecin